Home » Topics » BioWorld Science

BioWorld Science
RSS

Sinovent studies small-molecule human URAT1 inhibitor XNW-3009 in phase I

Dec. 10, 2019

FDA removes clinical hold on Abeona's phase III VIITAL study of EB-101

Dec. 10, 2019

LAIMU synthesizes new compounds for allergy

Dec. 10, 2019

Gilead Sciences identifies new benzamides for liver diseases

Dec. 10, 2019

Nerviano Medical Sciences presents new IDH1 and/or IDH2 mutant inhibitors

Dec. 10, 2019

Indivior selects CRO to conduct phase I study of INDV-2000

Dec. 10, 2019

Guangzhou Henovcom Bioscience discloses ENPP2 inhibitors

Dec. 10, 2019

Vedanta initiates first-in-patient study of VE-800 with Opdivo in advanced or metastatic cancer

Dec. 10, 2019

AMR Centre patents new antibacterials

Dec. 10, 2019

With reduced toxicity, can HSCT make it to Hall of Fame?

Dec. 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...